Thursday 16 October, 2025
Objectives: Pneumonia stands as a significant contributor to global infection-related mortality. Primarily bacterial in origin, pneumonia necessitates antibiotic treatment as…
Read moreAbstracts
A software for the estimation of absolute bioavailability from oral data exclusively: Towards the abolishment of microdosing studies in big pharma
Thursday 16 October, 2025
Introduction: The introduction of the finite absorption time (F.A.T.) concept [1,2] was followed by the development of the pertinent PBFTPK…
Read moreViral dynamic modeling of nirmatrelvir against SARS-CoV-2 in an in vitro infection model
Thursday 16 October, 2025
Objectives: The coronavirus disease 2019 (COVID-19) pandemic caused by the RNA-virus SARS-CoV-2 has shown the development of new antiviral agents….
Read morePopulation pharmacokinetics of cobicistat in once and twice daily regimens in various populations
Thursday 16 October, 2025
Objectives: Cobicistat (COBI) is a selective, mechanism-based inhibitor of the cytochrome P450 (CYP) 3A-enzyme.(1) COBI is approved for pharmacokinetic (PK)…
Read morepopulation pharmacokinetics and dose rationale for deferasirox in the treatment of iron overload in paediatric patients undergoing hematopoietic stem cell transplantation
Thursday 16 October, 2025
Introduction: Iron overload (IO) is common in adults and children with malignancies undergoing allogeneic haematopoietic stem cell transplantation (aHSCT) due…
Read moreComparison of oxazolidinones’ exposure-response for the treatment of tuberculosis
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) is one of the world’s deadliest infectious diseases, causing 1.3 million deaths in 2022. Treatment success rates are…
Read moreA Physiologically-Based Quantitative Systems Pharmacology (PB-QSP) Model for Individualized Prediction of Treatment Outcomes with Alogliptin in the Renal Impairment Population
Thursday 16 October, 2025
Introduction: Type 2 diabetes is considered to be one of the most significant health problems affecting the world, and prolonged…
Read morePredicting in vivo disposition of OATP substrates from in vitro kinetics using mechanistic PBPK modelling
Thursday 16 October, 2025
Objectives: In vitro systems are widely used in drug discovery to predict in vivo properties such as drug clearance, reducing…
Read moreEvaluating Drug Interactions Between Ritonavir and Hydrocodone: Implications From Physiologically Based Pharmacokinetic Simulation
Thursday 16 October, 2025
Introduction: Ritonavir is a protease inhibitor (PI) that is frequently used as a “booster” to increase the pharmacokinetic exposure to co-administered PIs[1]. Ritonavir as…
Read moreDeepARV-ChemBERTa: Ensemble Deep Learning to Predict Drug-Drug Interaction of Clinical Relevance with Antiretroviral Therapy
Thursday 16 October, 2025
Introduction: Drug-drug interaction (DDI) may result in toxicity or treatment failure of antiretroviral therapy (ARV) or comedications. Despite the high…
Read more